Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Abzena's Antitope subsidiary to share in Eurostars grant

A consortium of which Abzena subsidiary Antitope is a part has been awarded a €1.9mln grant under the Eurostars programme.
Abzena's Antitope subsidiary to share in Eurostars grant
The consortium is developing a novel treatment for clotting disorders

Abzena (LON:ABZA) said a consortium of which its Antitope subsidiary is a part has been awarded a €1.9mln grant under the Eurostars programme.

Other members of the consortium are: Prothix BV; Aristi Biotech BV; the University Medical Center Utrecht; and GenOnway.

The consortium is developing a novel treatment for clotting disorders, targeting anti-thrombin III, a protein that inhibits blood clotting. The novel antibody has the potential to both prevent and treat bleeding in patients with disorders such as haemophilia.

Neil Butt, vice president of Business Development at Abzena, said: "Applying our Composite Human Antibody technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients."

Antitope provides immunogenicity assessment, protein engineering to create humanised antibodies and de-immunised therapeutic proteins, and cell line development for manufacture.

The Eurostars Programme is a European joint programme dedicated to giving a leg-up to small-to-medium sized research & development companies.

Shares in Abzena were up 1.8% at 56p in morning trade.

John-H.jpg
Why Invest In Abzena plc? Read More Here

Register here to be notified of future ABZA Company articles
View full ABZA profile

Abzena plc Timeline

Big Picture
June 14 2016

Related Articles

Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
Pollen2.jpg
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.
757z468_Lab-(1).jpg
April 26 2016
Dr Stewart White, Collagen Solutions chief executive, told investors that the new partnership will expedite the roll-out of its medical grade collagen to customers in China.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.